Seroatlas · Human Serome Atlas

FGF22

Fibroblast growth factor 22

Also known as: FGF22_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9HCT0
Gene: FGF22
Ensembl: ENSG00000070388
Chromosome: 19
Canonical length: 170 aa
Protein class: Predicted secreted proteins, RAS pathway related proteins
Secretome location: Secreted in other tissues

OverviewNCBI Gene

The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. The mouse homolog of this gene was found to be preferentially expressed in the inner root sheath of the hair follicle, which suggested a role in hair development. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]

Canonical amino-acid sequenceUniProt

170 residues, UniProt reviewed canonical sequence.

>Q9HCT0|FGF22
     1  MRRRLWLGLA WLLLARAPDA AGTPSASRGP RSYPHLEGDV RWRRLFSSTH FFLRVDPGGR
    61  VQGTRWRHGQ DSILEIRSVH VGVVVIKAVS SGFYVAMNRR GRLYGSRLYT VDCRFRERIE
   121  ENGHNTYASQ RWRRRGQPMF LALDRRGGPR PGGRTRRYHL SAHFLPVLVS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FGF22 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 13 nTPM

Expression across tissuesHPA

Tissue

skin: 13 nTPM
cerebral cortex: 5.6 nTPM
basal ganglia: 3.8 nTPM
amygdala: 3.7 nTPM
hypothalamus: 3.6 nTPM
hippocampal formation: 3.4 nTPM

Single-cell type

retinal horizontal cells: 12 nCPM
retinal amacrine cells: 9.2 nCPM
ovarian stromal cells: 8.4 nCPM
esophageal apical cells: 7.3 nCPM
syncytiotrophoblasts: 6.6 nCPM
müller glia: 6.1 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 5.2 nTPM
white matter: 5 nTPM
thalamus: 4.8 nTPM
pons: 4.3 nTPM
amygdala: 4.2 nTPM
midbrain: 4.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.93
gnomAD pLI: 0
gnomAD missense Z: -0.8
DepMap mean gene effect: 0.11
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FGF22 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FGF22 as an antibody target. Whether an autoantibody or antibody against FGF22 could matter depends on whether native FGF22 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FGF22 is annotated as secreted, so native FGF22 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label FGF22 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...